SPG302: A Synaptic Regenerative Treatment Option for Schizophrenia
SPG601 found to reduce measure of abnormal brain activity in fragile X
FDA Grants Fast Track Designation to Spinogenix’s SPG601 for Treatment of FXS
FDA Designation for SPG601 Highlights New Hope for FXS Treatment
Novel BK Channel Activator Fast Tracked for Fragile X Syndrome
Personalized medicine; astroglia organoids; fast track for fragile X drug
Spinogenix’s SPG601 Receives FDA Fast Track Designation for Fragile X Syndrome
FDA grants fast-track designation to small molecule for Fragile X
Rewiring the Brain… Dr. Peter Vanderklish, Chief Scientific Officer, Spinogenix
Companies To Watch: Spinogenix
